Nymox Pharmaceutical (NYMX) Return on Equity ROE from the fourth quarter 2024 to fourth quarter 2023 and annually, average high and low, overall ranking from Dec 31 2024 to Dec 31 2023 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Nymox Pharmaceutical Corporation  (NYMX)

Nymox Pharmaceutical's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Nymox Pharmaceutical in the fourth quarter 2024?
Due to the lack of equity, it was not possible to calculate Nymox Pharmaceutical Corporation's return on equity (ROE) in its fourth quarter 2024

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Dec 31 2024)
IV. Quarter		 0
III. Quarter		 0
II. Quarter		 0
I. Quarter		 (Dec 31 2023)
IV. Quarter
Y / Y Equity Change - - - - -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -4 -9 -9 -9 -10
Return On Equity (TTM) - - - - -
NYMX's Total Ranking # # # # #
Equity (TTM) in Millions -7 -6 -7 -7 -3
Seq. Equity Change - - - - -
Seq. Net Income Change - - - - -

Back to NYMX Management Effectiveness >> NYMX's 5 Years Annual ROE >> Compare NYMX ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry #
Sector #
Overall #

Return On Equity Statistics
High Average Low
0 %
0 %
0 %
 





NYMX Annual Return On Equity (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021		 (Dec 31 2020)
2020
Total Equity in Millions -7 -3 0 -1 2
Y / Y Equity Change - - - - -37.79 %
Net Income in Millions -4 -9 -7 -13 -12
Y / Y Net Income Change - - - - -
Return On Equity - - - - -547.23 %

Back to NYMX Management Effectiveness >> NYMX's 5 Years Annual ROE >> Compare NYMX ROE to its Competitors




More Return On Equity Ratios
In Vitro & In Vivo Diagnostic Substances Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
NYMX's' Return on Equity at Yahoo Finance
NYMX's Roe Ratio versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for NYMX's Competitors
Subscribers only: Roe for Nymox Pharmaceutical's Suppliers
Subscribers only: Return On Equity for NYMX's Customers




Companies with similar Return On Equity at Dec 31 2024, within Healthcare Sector ROE
Davita Inc   168.73 %
Longduoduo Co Ltd  167.17 %
Halozyme Therapeutics Inc   138.37 %
Tao Synergies Inc   96.43 %
3m Company  95.68 %
Biomx Inc  88.72 %
Adma Biologics Inc   85.68 %
Earth Science Tech Inc   85.13 %
Eli Lilly And Company  76.84 %
Tenet Healthcare Corp  76.52 %
Addex Therapeutics Ltd  75.10 %
Novo Nordisk A  73.56 %
Abbvie Inc   70.54 %
Nrc Health  69.30 %
Amgen Inc   67.18 %
Dariohealth Corp   61.81 %
Agios Pharmaceuticals Inc   58.94 %
Idexx Laboratories Inc  55.82 %
Exelixis Inc   54.88 %
Promis Neurosciences inc   51.55 %
Medpace Holdings Inc   51.48 %
Zoetis Inc   49.70 %
Pharmacyte Biotech Inc   49.09 %
Edwards Lifesciences Corporation  48.53 %
Protagonist Therapeutics inc   47.67 %
Sbc Medical Group Holdings Incorporated  47.47 %
Carlisle Companies Incorporated  47.32 %
Puma Biotechnology Inc   46.10 %
Galmed Pharmaceuticals Ltd   45.94 %
Waters Corporation  41.68 %

Date modified: 2026-08-31T09:28:23+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.